TY - JOUR
T1 - Nobiletin, a citrus flavonoid, improves cognitive impairment and reduces soluble Aβ levels in a triple transgenic mouse model of Alzheimer's disease (3XTg-AD)
AU - Nakajima, Akira
AU - Aoyama, Yuki
AU - Shin, Eun Joo
AU - Nam, Yunsung
AU - Kim, Hyoung Chun
AU - Nagai, Taku
AU - Yokosuka, Akihito
AU - Mimaki, Yoshihiro
AU - Yokoi, Tsuyoshi
AU - Ohizumi, Yasushi
AU - Yamada, Kiyofumi
N1 - Funding Information:
We thank Drs. Y. Ohya and K. Yano, Division for Research of Laboratory Animals, Nagoya University, for their technical assistance. This work was supported in part by Grants for Project Research (Development of Fundamental Technology for Analysis and Evaluation of Functional Agricultural Products and Functional Foods) from the Ministry of Agriculture, Forestry and Fisheries of Japan, Grants-in-aid for Scientific Research 23659135 , 24111518 , 25116515 , and 26670121 from the Japan Society for the Promotion of Science , and grants from the Research Foundation for Oriental Medicine and the Public Foundation of Chubu Science and Technology Center.
Publisher Copyright:
© 2015 Elsevier B.V.
PY - 2015/8/1
Y1 - 2015/8/1
N2 - Alzheimer's disease (AD), the most common form of dementia among the elderly, is characterized by the progressive decline of cognitive function. Increasing evidence indicates that the production and accumulation of amyloid β (Aβ), particularly soluble Aβ oligomers, is central to the pathogenesis of AD. Our recent studies have demonstrated that nobiletin, a polymethoxylated flavone from citrus peels, ameliorates learning and memory impairment in olfactory-bulbectomized mice, amyloid precursor protein transgenic mice, NMDA receptor antagonist-treated mice, and senescence-accelerated mouse prone 8. Here, we present evidence that this natural compound improves cognitive impairment and reduces soluble Aβ levels in a triple transgenic mouse model of AD (3XTg-AD) that progressively develops amyloid plaques, neurofibrillary tangles, and cognitive impairments. Treatment with nobiletin (30mg/kg) for 3 months reversed the impairment of short-term memory and recognition memory in 3XTg-AD mice. Our ELISA analysis also showed that nobiletin reduced the levels of soluble Aβ1-40 in the brain of 3XTg-AD mice. Furthermore, nobiletin reduced ROS levels in the hippocampus of 3XTg-AD as well as wild-type mice. These results suggest that this natural compound has potential to become a novel drug for the treatment and prevention of AD.
AB - Alzheimer's disease (AD), the most common form of dementia among the elderly, is characterized by the progressive decline of cognitive function. Increasing evidence indicates that the production and accumulation of amyloid β (Aβ), particularly soluble Aβ oligomers, is central to the pathogenesis of AD. Our recent studies have demonstrated that nobiletin, a polymethoxylated flavone from citrus peels, ameliorates learning and memory impairment in olfactory-bulbectomized mice, amyloid precursor protein transgenic mice, NMDA receptor antagonist-treated mice, and senescence-accelerated mouse prone 8. Here, we present evidence that this natural compound improves cognitive impairment and reduces soluble Aβ levels in a triple transgenic mouse model of AD (3XTg-AD) that progressively develops amyloid plaques, neurofibrillary tangles, and cognitive impairments. Treatment with nobiletin (30mg/kg) for 3 months reversed the impairment of short-term memory and recognition memory in 3XTg-AD mice. Our ELISA analysis also showed that nobiletin reduced the levels of soluble Aβ1-40 in the brain of 3XTg-AD mice. Furthermore, nobiletin reduced ROS levels in the hippocampus of 3XTg-AD as well as wild-type mice. These results suggest that this natural compound has potential to become a novel drug for the treatment and prevention of AD.
UR - http://www.scopus.com/inward/record.url?scp=84928746754&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84928746754&partnerID=8YFLogxK
U2 - 10.1016/j.bbr.2015.04.028
DO - 10.1016/j.bbr.2015.04.028
M3 - Article
C2 - 25913833
AN - SCOPUS:84928746754
SN - 0166-4328
VL - 289
SP - 69
EP - 77
JO - Behavioural Brain Research
JF - Behavioural Brain Research
ER -